Grunenthal has patented an abuse-proofed oral dosage form with controlled opioid release for once daily administration. The dosage form includes opioids with abuse potential, polymers, and other auxiliary substances, with a breaking strength of at least 500 N. The product is not a result of extrusion and does not contain opioid antagonists. GlobalData’s report on Grunenthal gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Grunenthal, Human telomerase RT biomarker was a key innovation area identified from patents. Grunenthal's grant share as of January 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11844865B2) discloses an abuse-proofed oral dosage form designed for once-daily administration, featuring controlled opioid release. The dosage form is not a product of extrusion and includes at least one opioid with abuse potential, such as hydrocodone, in a delayed-release matrix. The formulation comprises polyethylene oxide, cellulose ether, and optional auxiliary substances like wax and delayed-release coatings. Notably, the abuse-proofed oral dosage form exhibits a breaking strength of at least 500 N and does not contain an antagonist for the opioid, ensuring its effectiveness in combating pain for a duration of one day.
Furthermore, the patent details a process for producing the abuse-proofed oral dosage form, involving the mixing of components, forming a mixture, and applying force with or without heating to achieve the desired breaking strength. The process may include pelletization, grading by size, and the application of delayed-release coatings. The resulting dosage form, with a breaking strength of at least 500 N, is suitable for once-daily administration and offers a novel approach to combatting pain while minimizing the risk of abuse. Additionally, the patent covers methods of treating pain using the disclosed dosage form, highlighting its potential impact on pain management strategies for patients in need of such treatment.
To know more about GlobalData’s detailed insights on Grunenthal, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
